Results 291 to 300 of about 176,622 (333)

The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis. [PDF]

Discov Oncol
Dai Q, Tang J, Du T, Huang Q.
europepmc   +1 more source

Supplemental Figure S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

William Kelly, Adolfo Enrique Diaz Duque, Joel Michalek, Brandon Konkel, Laura Caflisch, Yidong Chen, Sarath Chand Pathuri, Vinu Madhusudanannair-Kunnuparampil, John Floyd, Andrew Brenner   +9 more
openalex   +1 more source

Pigment Epithelium-Derived Factor (PEDF)-Based Therapy Induced Photoreceptor Survival by Stabilizing Choroidal Neovessels in a VEGF Overexpression CNV Rat Model. [PDF]

FASEB J
Tschulakow AV, Xi L, Schraermeyer U, Julien S.   +3 more
europepmc   +1 more source

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J Nielsen, Jérôme Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini   +24 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bevacizumab

Nature Reviews Drug Discovery, 2005
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Lee M. Ellis, Peter Kirkpatrick
openaire   +2 more sources

The safety of bevacizumab

Expert Opinion on Drug Safety, 2006
Despite the significant gains made in the treatment of many cancers over the last few decades, further improvements in survival using traditional chemotherapeutic agents have now begun to plateau. The development of bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, has provided promise for continued gains in ...
Rachel E, Sanborn, Alan B, Sandler
openaire   +2 more sources

Bevacizumab

Reactions Weekly, 2017
  +8 more sources

Bevacizumab

Reactions Weekly, 2013
  +6 more sources

Bevacizumab

Reactions Weekly, 2019
  +7 more sources